首页> 美国卫生研究院文献>other >Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient

【2h】

Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient

机译：阿帕替尼联合吉西他滨治疗晚期胰腺癌患者的恶性腹水

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Rationale:Malignant ascites (MA) is one of the poor prognostic factors for advanced pancreatic cancer and can bring about serious symptoms. The improvement of quality of life for patients is priority. However, there is no standard method for the treatment for pancreatic cancer-mediated MA. Apatinib is a novel and highly selective tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2. There are no reports of concurrent apatinib with gemcitabine in patients with pancreatic cancer-mediated MA.

机译：理由：恶性腹水（MA）是晚期胰腺癌的不良预后因素之一，可带来严重的症状。改善患者生活质量是当务之急。但是，尚无用于治疗胰腺癌介导的MA的标准方法。 Apatinib是靶向血管内皮生长因子受体2的新型，高度选择性的酪氨酸激酶抑制剂。没有报道在胰腺癌介导的MA患者中同时使用阿帕替尼和吉西他滨。

著录项

期刊名称 other
作者
Lijun Liang; Lei Wang; Panrong Zhu; Youyou Xia; Yun Qiao; Kaiyuan Hui; Chenxi Hu; Yan Ren; Xiaodong Jiang;
展开▼
作者单位

展开▼
年(卷),期 -1(96),47
年度 -1
页码 e8725
总页数 4
原文格式 PDF
正文语种
中图分类
关键词
apatinib gemcitabine malignant ascites pancreatic cancer;

机译：阿帕替尼;吉西他滨;恶性腹水;胰腺癌;

相似文献

外文文献
中文文献
专利

1. A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. [J] . Kuemmerle A, Decosterd LA, Buclin T, Cancer chemotherapy and pharmacology. . 2009,第2期

机译：吉西他滨对晚期胰腺癌和顽固性恶性腹水患者低氧腹部停流灌流的I期药代动力学研究。
2. A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites [J] . Andrea Kuemmerle, Laurent A. Decosterd, Thierry Buclin, Cancer Chemotherapy and Pharmacology . 2009,第2期

机译：吉西他滨低氧腹部停流灌流治疗晚期胰腺癌和顽固性恶性腹水的I期药代动力学研究
3. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine|[sol]|cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer |[ndash]| a multi-centre randomised phase II study [J] . R Wilkowski, S Boeck, S Ostermaier, British Journal of Cancer . 2009,第11期

机译：并发吉西他滨和顺铂联合或不联合吉西他滨| [sol] |顺铂的放化疗与放疗联合5-氟尿嘧啶的局部放化疗| [ndash] |多中心随机II期研究
4. Dual Delivery Nanoscale Device for miR-345 and Gemcitabine Co-Delivery to Treat Pancreatic Cancer [C] . Metin Uz, Satyanaravana Rachagani, Surinder K. Batra, Society for Biomaterials annual meeting and exposition . 2017

机译：用于miR-345和吉西他滨共同递送的双递送纳米装置可治疗胰腺癌
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study [O] . R Wilkowski, S Boeck, S Ostermaier, 2009

机译：局部晚期胰腺癌患者中同时进行吉西他滨和顺铂联合放化疗或不联合进行吉西他滨/顺铂化疗与同期5-氟尿嘧啶放化疗联合5-氟尿嘧啶治疗
7. Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient [O] . Lijun Liang, Lei Wang, Panrong Zhu, 2017

机译：Apatinib并发吉西他滨控制晚期胰腺癌患者恶性腹水

Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient

摘要

著录项

相似文献

相关主题

期刊订阅